Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Addex Therapeutics Ltd. (ADXN)
Price$2.81Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CHF29,972 | CHF410,042 | CHF1.6M | CHF1.4M | CHF3.2M | CHF3.9M | CHF2.8M | CHF6.7M | CHF499,894 |
| Research & development | CHF190,190 | CHF854,305 | CHF1.2M | CHF8.2M | CHF12.8M | CHF10.4M | CHF12.5M | CHF4.9M | CHF2.6M |
| Operating expenses | CHF2.8M | CHF3.2M | CHF3.9M | CHF12.0M | CHF18.7M | CHF16.1M | CHF17.4M | CHF8.1M | CHF3.7M |
| Operating income | −CHF2.8M | −CHF2.8M | −CHF2.2M | −CHF10.5M | −CHF15.5M | −CHF12.2M | −CHF14.6M | −CHF1.4M | −CHF3.2M |
| Operating margin | −9,390.76% | −671.94% | −138.70% | −729.49% | −491.74% | −315.62% | −515.38% | −21.25% | −647.15% |
| EBITDA | −CHF6.8M | −CHF2.4M | −CHF2.2M | −CHF10.5M | −CHF15.2M | −CHF11.9M | −CHF14.3M | −CHF1.4M | −CHF3.2M |
| EBITDA margin | −22,793.59% | −580.47% | −137.97% | −728.88% | −480.71% | −305.85% | −503.60% | −21.21% | −644.10% |
| Net income | −CHF6.7M | CHF7.1M | −CHF10.6M | −CHF20.8M | −CHF15.4M | −CHF12.9M | −CHF14.8M | −CHF1.6M | −CHF3.3M |
| Net profit margin | −22,448.44% | 1,720.75% | −652.75% | −1,439.78% | −486.85% | −331.48% | −521.61% | −24.54% | −656.22% |
| Basic EPSper basic share | -CHF 7.20 | CHF 0.07 | -CHF 0.14 | -CHF 0.46 | -CHF 0.45 | -CHF 0.48 | -CHF 0.56 | -CHF 0.07 | -CHF 0.25 |
| Diluted EPSper diluted share | -CHF 7.20 | CHF 0.07 | -CHF 0.14 | -CHF 0.46 | -CHF 0.45 | -CHF 0.48 | -CHF 0.56 | -CHF 0.07 | -CHF 0.25 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
UBS Group AG | 47 |
SBI Securities Co., Ltd. | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Addex reports limited cash as half-year loss reaches CHF3.46 million
Addex Therapeutics ($ADXN) reported a first-half net loss of CHF3.46 million, compared with CHF3.31 million a year earlier. Its operating loss narrowed to CHF1.13 million, but the share of losses from associates increased to CHF2.33 million ...
